GNLX
What one share of Genelux holds
Pharmaceutical Preparations
Genelux’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.86 |
|---|---|
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$0.69 |
| Cash and investments | $0.20 |
| Book value | $0.36 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$0.57 | $0.01 | −$0.40 | — | −$3.92 |
| 2023 | $0.01 | −$1.16 | $0.04 | −$0.87 | — | $0.73 |
| 2024 | $0.00 | −$0.95 | $0.01 | −$0.69 | — | $0.76 |
| 2025 | $0.00 | −$0.86 | $0.03 | −$0.71 | — | $0.30 |